Epiandrosterone

Epi-andro is not itself a meaningful androgen receptor agonist — it's a pro-drug. The whole point of the molecule is that it sits one enzymatic step upstream of 5α-dihydrotestosterone (DHT), and your own liver does the conversion. Everything the compound "does" in the mirror is downstream of that hand-off.

Two-Step Enzymatic Conversion to DHT#

Epiandrosterone is a 5α-reduced, 3β-hydroxy C19 steroid — structurally, DHT with the wrong hydroxyl on the A-ring and the wrong oxidation state at C17. Hepatic 3β-hydroxysteroid dehydrogenase (3β-HSD / 3β-HSOR) oxidizes the 3β-OH to a ketone, producing 5α-androstane-3,17-dione. 17β-HSD then reduces the C17 ketone to a β-hydroxyl, yielding DHT (stanolone).

"Epiandrosterone, which is the 5α-reduced DHEA with a 3β-hydroxy-5α-androstan-17-one structure, exhibits androgenic activity after its enzymatic oxidation by 3β-hydroxysteroid dehydrogenase (3β-HSD) and subsequent reduction to DHT." — El Kihel, L. Steroids, 2012

"It was shown that DHEA and epiandrosterone serve as substrates for human hepatic 3beta-hydroxysteroid oxidoreductase (HSOR), leading to the formation of 5α-androstanedione and ultimately to DHT." — Chalbot S, Morfin R. Drug Metab Dispos, 2005

Practical consequence: because DHT is generated downstream of 5α-reductase, finasteride and dutasteride will not protect your hairline on epi-andro. If you're MPB-prone, topical AR antagonists (RU58841, pyrilutamide) are the only mechanistically sensible scalp defense on cycle.

DHT at the Androgen Receptor — Dry, Hard, No Estrogen#

DHT binds the androgen receptor with roughly three times the affinity of testosterone and dissociates more slowly, producing stronger per-molecule AR signalling in skeletal muscle, CNS, and sebaceous tissue. That drives the usual AR-mediated physique outcomes: increased myofibrillar protein synthesis, amino-acid uptake, satellite cell activation, and strength-per-bodyweight.

The defining feature for physique users is what DHT cannot do: the A-ring is already saturated, so the molecule is not a substrate for aromatase. No estrogen conversion, no water retention, no gyno risk, no E2-driven fat patterning. This is why the subjective feel of an epi-andro run is "harder, drier, tighter" rather than "fuller, heavier, wetter" — you're running a purely androgenic signal with no estrogenic counterweight. It's also why the scale barely moves while the mirror improves: dry lean tissue and reduced subcutaneous water, not glycogen-and-fluid bulk.

Why Oral Bioavailability Is the Whole Game#

Epiandrosterone taken as raw powder is largely wasted. Orally dosed 17-ketosteroids in this family undergo aggressive first-pass sulfation and glucuronidation in the gut wall and liver before they can even reach the 3β-HSD conversion step.

"Oral administration of dehydroepiandrosterone and related androstane derivatives results in extensive first-pass hepatic metabolism with a bioavailability of approximately 3% in primate models." — Leblanc M et al. J Clin Endocrinol Metab, 2003

Practical consequence: the commercial products that work (cyclodextrin-complexed, liposomal, "Cyclosome") aren't marketing gimmicks — the delivery format is doing most of the work. A 500 mg/day dose of unformulated powder delivers a fraction of a 330 mg/day dose of a properly complexed product. Always dose with dietary fat to exploit lymphatic uptake and bypass a portion of first-pass.

Non-Methylated Structure — Minimal Hepatotoxicity#

Unlike true 17α-alkylated orals (superdrol, M1T, epistane, dianabol), epiandrosterone has no C17α methyl group. It doesn't need one — it's not trying to survive first-pass as the active molecule; it's trying to reach the liver and get converted there. That structural choice is the reason AST/ALT typically stay in range on standard doses, and it's the single biggest reason epi-andro gets tolerated for 6–8 week cycles where a real methyl like M1T would be a 2–4 week proposition.

TUDCA at 250–500 mg/day is reasonable precaution, not a mechanistic necessity. The real organ system taking the hit on this compound is your lipid panel, not your hepatocytes.

Off-Target Pharmacology Worth Knowing#

Epiandrosterone has a few non-AR actions that matter at higher doses:

• L-type calcium channel blockade in cardiac myocytes — documented in vitro and relevant at supraphysiological exposures.

"Epiandrosterone blocks L-type Ca²⁺ channels in ventricular myocytes at micromolar concentrations, resulting in a negative inotropic effect that could become relevant at supraphysiological exposures." — Gupte SA et al. J Mol Cell Cardiol, 2002

• Weak GABA-A negative allosteric modulation — contributes to the mild mood-lift / stimulatory feel some users report, similar to other 3β-hydroxy neurosteroids.
• G6PDH / pentose phosphate pathway inhibition — cited historically as the rationale for epiandrosterone's "hypolipidemic" label in early literature, though in practice oral androgen exposure dominates and lipids trend worse on cycle, not better.

Net Practical Picture#

You're taking an oral pro-drug that your liver converts into DHT. You get dry strength, AR-driven hardness, no aromatization, no serious hepatotoxicity, and suppressed HPTA output that needs a proper SERM PCT on the back end. The side-effect profile — HDL drop, accelerated scalp loss in genetically susceptible users, mild BP creep, prostate sensitivity — is the DHT profile, full stop. Manage those on cycle (bergamot/fish oil, topical AR antagonist, daily low-dose tadalafil) and epi-andro is one of the cleaner grey-market tools for a dry recomp or hardening finisher.

Common (most users)#

• Oily skin and acne — DHT is doing what DHT does. Daily salicylic acid cleanser, niacinamide serum, and keeping dietary dairy/sugar in check handle most of it. If it's escalating to cystic, the dose is too high or the individual's genetics may not tolerate DHT loads.
• Accelerated scalp hair shedding (if MPB-prone) — this is the single most common reason users quit epi-andro. Oral 5AR inhibitors will not save you here — the DHT is delivered downstream of 5α-reductase. Topical RU58841 or pyrilutamide (AR antagonists at the follicle) are the only mechanistically valid scalp defenses during a cycle. If a receding hairline is already present, choose an alternative compound.
• Libido swings — strong libido and morning wood for the first 2–3 weeks, then a dropoff as HPTA suppression kicks in. Daily tadalafil 2.5–5 mg smooths this out and pulls double duty for BP and prostate.
• Aggression / assertiveness uptick — typical DHT tone. Usually wanted. Keep it out of the cage in week 3–4 when sleep may also be lighter.
• Mild BP rise — cuff at home 2–3×/week. Citrus bergamot, cardio 3×/week, and sodium discipline keep it in check. If resting is pushing past 135/85, back down.
• "Flat" look for the first 7–10 days — epi-andro doesn't aromatize, so you lose the estrogenic water softness early in the cycle before the DHT hardening kicks in. Don't panic-dose higher.

Uncommon (dose-dependent or individual)#

• Lipid drag — HDL down, LDL up. Predictable for any oral non-aromatizing androgen, even without 17α-alkylation. Get a baseline panel pre-cycle and recheck at week 3–4. If HDL drops below 35 mg/dL or LDL goes past 160, cut the dose or end the cycle early. Citrus bergamot 500–1000 mg/day and fish oil 2–4 g/day are the standard blunting stack.
• Prostate fullness / frequent urination — DHT-mediated prostatic growth. Daily tadalafil 2.5–5 mg resolves this for most users. If it persists or there's hesitancy/incomplete voiding, pull the cycle.
• Mood / sleep disruption at higher doses (600–750 mg/day) — light sleep, waking hot, increased irritability. Drop to 400–500 mg/day.
• Suppressed morning wood by week 4–5 — expected signal that LH/FSH are down. Not a problem during the cycle; it's the reason PCT is non-negotiable.
• Gut / GI upset — usually the formulation, not the molecule. Take with meals containing fat.

Rare but serious#

• Hypertensive crisis — anyone running epi-andro on top of untreated hypertension is courting this. Warning signs: headache that won't quit, visual disturbance, resting BP >160/100. Stop immediately.
• Cardiac symptoms at supraphysiological exposures — high-dose in vitro work shows L-type Ca²⁺ channel blockade and negative inotropy in ventricular myocytes.

"Epiandrosterone blocks L-type Ca2+ channels in ventricular myocytes at micromolar concentrations, resulting in a negative inotropic effect that could become relevant at supraphysiological exposures." — Gupte et al., J Mol Cell Cardiol (2002)

Clinically relevant only at abusive doses, but it's the mechanistic reason mega-dosing this compound is a bad idea.

• Persistent HPTA suppression past a standard 4-week PCT — uncommon at 4–6 week cycle lengths, more likely with 8-week runs or back-to-back cycles without full recovery. Bloodwork (LH, FSH, total T) 6–8 weeks post-PCT is how you catch it. If T is still suppressed, you need an endocrinology workup, not another PCT round.
• Severe acne / scarring breakouts — in genetically susceptible users, epi-andro can trigger the kind of cystic acne that needs isotretinoin to resolve. If the first 2 weeks show aggressive cystic activity, end the cycle.

Hard contraindications#

• Active or prior prostate cancer or hormone-sensitive cancer — DHT drives growth. Non-negotiable.
• Untreated hypertension or dyslipidemia — control these before you start an oral androgen, not while you're running one.
• Planned conception within the next 6 months — HPTA suppression hits LH/FSH and semen parameters. Finish a cycle, run full PCT, recheck bloodwork, then try.
• Pregnancy or possibility of pregnancy — androgens are teratogenic to a female fetus. Do not handle or dose.
• Female use — epi-andro converts to DHT in vivo. Virilization (voice deepening, clitoral enlargement, androgenic hair pattern changes) is real and past a threshold is not reversible. Women looking for recomp have better tools.
• Tested athletes — WADA-banned and detectable on standard urinary androgen-metabolite panels via epiandrosterone-glucuronide. There is no "clean" window.
• Advanced male pattern baldness where hair retention matters to you — this is a DHT delivery vehicle. That's the entire mechanism. Pick a different compound.

Gender & PCT considerations#

Women: not recommended at any dose. The DHT conversion pathway is the whole point of the compound, and the virilization risk it carries (voice, clitoral tissue, androgenic hair pattern) has a partial-irreversibility threshold that sneaks up on users. Anavar or low-dose primobolan are the conventional female-tolerable picks — epi-andro isn't.

Men — PCT: run it, even though the marketing calls this a "mild" prohormone. Bloodwork from 6-week users consistently shows meaningful LH/FSH drops.

Support: natural test-support stack (DAA, tongkat, ashwagandha) layered on top is fine but not a substitute for a SERM. Recheck total T, LH, and FSH 4 weeks after PCT ends to confirm recovery before planning the next cycle. Give lipids 6–8 weeks clean between runs — don't blast-and-cruise a prohormone.